Press Releases for CELG

Press Releases
Agennix AG Reports Financial Results for Third Quarter and First Nine Months of 2009
MethylGene Reports Third Quarter 2009 Financial Results
Celgene Reports Record Third Quarter 2009 Operating and Financial Results
Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2009
Clinical Data Evaluating Amrubicin® as Potential Therapy for Patients with Small Cell Lung Cancer Presented at 13th World Conference on Lung Cancer
VIDAZA Upgraded to Category 1 Based on Unprecedented Survival and Selected Preferred Treatment for Intermediate-2 and High-Risk Myelodysplastic Syndromes by the National Comprehensive Cancer Network (NCCN) in Its Clinical Practice Guidelines
Celgene Corporation to Present at Two Upcoming Investor Conferences
MethylGene Reports Second Quarter 2009 Financial Results
Celgene Reports Record Second Quarter 2009 Operating and Financial Results
Celgene Corporation to Announce Second Quarter Results on July 23, 2009
Celgene Corporation to Present at Two Upcoming Investor Conferences
Celgene Announces Positive Top Line Data from Randomized Controlled Phase II Study of Apremilast in Psoriatic Arthritis
Free Growth Strategy Report on PETM, QCOM, CELG and NVAX By MaybachFinancial.Com
Celgene Corporation to Present at Three Upcoming Investor Conferences
Colorado Again Confirmed As Top Bioscience State By National Rankings & Venture Capital Funding Activity
GPC Biotech Reports Financial Results for First Quarter 2009
59 Presentations and Posters Evaluating Celgene Products to Be Highlighted at the 45th American Society of Clinical Oncology Meeting
Celgene Corporation to Present at the Sanford C. Bernstein & Co. Strategic Decisions Conference 2009
Celgene Corporation to Present at the Eighth Annual JMP Securities Research Conference
WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board
Celgene Corporation to Present at the Deutsche Bank 34th Annual Health Care Conference
GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance
Celgene Corporation to Present at Baird’s 2009 Growth Stock Conference
Celgene Corporation to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
MethylGene Reports First Quarter 2009 Financial Results
Celgene Reports First Quarter 2009 Operating and Financial Results
Celgene Announces Share Repurchase Program
Celgene Corporation to Announce First Quarter Results on April 30, 2009
Beacon Equity Issues Trade Alerts on Market Movers: CREE, TTWO, CELG, LVS, APL, AU
Celgene Corporation to Present at the 4(th) Annual Citi Biotech Conference
MethylGene Reports Fourth Quarter and Full Year 2008 Financial Results
Celgene Corporation to Present at 4th Annual Citi Biotech Day
Celgene Corporation to Present at the Needham & Company, LLC Cancer Therapeutics: Today and Tomorrow Conference
Celgene Corporation to Present at the Cowen and Company 29th Annual Health Care Conference
Celgene Corporation to Present at the Barclays Capital Global Healthcare Conference
70 Abstracts Evaluating the Potential of Celgene Products in Multiple Myeloma to Be Presented at the 12th International Myeloma Workshop
Landmark Study Published in The Lancet Oncology Shows Celgene’s Vidaza® Demonstrates Unprecedented Overall Survival in Intermediate-2 and High-Risk Myelodysplastic Syndromes, as Well as Acute Myeloid Leukaemia
Celgene Corporation to Present at the 11th Annual BIO CEO Investor Conference
Research and Markets: The Acquisition of Serono Fulfills, In Part, Merck Group Plans To Increase Its Pharma Presence in the US - Feb 4 2009 11:57PM
Research and Markets: The Acquisition of Serono Fulfills, In Part, Merck Group Plans To Increase Its Pharma Presence in the US - Feb 4 2009 12:00PM
BenchmarkJournal.Com (Complimentary) Analyst Review for CELG, SIAL, BMRN and BEAV
Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits
Celgene Corporation Reviews 2008 Achievements and Announces 2009 Financial Outlook
Celgene Corporation to Present at the 27th Annual JPMorgan Healthcare Conference
Zacks Analyst Blog Highlights: Celgene Corp., Cytori Therapeutics, CAI International, Inc., Sinopec and Smith Micro Software, Inc.
Zacks Bull and Bear of the Day Highlights: Celgene Corp., Marriott International, Fannie Mae, Newmont Mining and Barrick Gold
European Commission Grants VIDAZA® Full Marketing Authorization for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukaemia (AML)
BenchmarkJournal.Com (Complimentary) Analyst Review for ITU, RIO, CELG and UAUA
Celgene Corporation and Acceleron Pharma to Present ACE-011 Data at the 50th Annual Meeting of the American Society of Hematology
Celgene Corporation to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period
Celgene Cellular Therapeutics Receives FDA Clearance for First Placenta-Derived Stem Cell Clinical Study
Celgene Corporation to Present at the 2008 Credit Suisse Annual Health Care Conference
Celgene Corporation to Present at the Rodman & Renshaw Annual Global Investment Conference
Market Pulse Announces Its Hot Stock Alerts for Thursday, November 6, 2008: PRRY, CELG, CEGE, AMZN
Celgene Corporation to Present at the Oppenheimer 19th Annual Healthcare Conference
Seven Summits Research Releases Alerts on HIG, PG, APA, CELG, and SPLS
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
Celgene Reports Record Third Quarter 2008 Product Sales and Operating Profits
Celgene Corporation to Announce Third Quarter Results on October 23, 2008
Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients with Multiple Myeloma
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma
Celgene Corporation to Present at the Third Annual JMP Securities Healthcare Focus Conference
Celgene Corporation to Present at the UBS 2008 Global Life Sciences Conference
Celgene Corporation to Present at the Bank of America 38th Annual Investment Conference
Celgene Corporation to Present at Merrill Lynch Global Pharmaceutical Biotech and Medical Devices Conference
Celgene Corporation to Present at Morgan Stanley Global Healthcare Unplugged Conference
Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy
Celgene Corporation to Present at the 3rd Annual Citi Biotech Day
Celgene Corporation to Present at the Thomas Weisel Partners Experts in Growth Healthcare Conference 2008
Celgene Corporation to Present at the NewsMakers in the Biotech Industry Conference
Zacks Analyst Interview Highlights: Genentech, ImClone Systems, Bristol-Myers Squibb and Celgene
"Stock Alert" Members Recently Book Profits As High As 20% Per Trade
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
Celgene Corporation to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Celgene Corporation to Present at the BMO Capital Markets 2008 Focus on Healthcare Conference
Celgene Reports Record Second Quarter 2008 Product Sales and Operating Profits
Celgene Corporation to Announce Second Quarter 2008 Results
Seven Summits Research Releases Comments on GOOG, ABX, CELG, RF, and BKC
Seven Summits Research Releases Alerts on GS, WB, OXY, PCX, and CELG
Celgene Corporation to Present at Jefferies 2nd Annual Healthcare Conference
Clinical Data For REVLIMID(R) And VIDAZA(R) In Important Blood Cancers Presented at The 13th European Hematology Association Congress
Celgene Corporation to Present at William Blair & Company's 28th Annual Growth Stock Conference
REVLIMID(R) Data for Newly Diagnosed Multiple Myeloma Reported at a Satellite Symposium During the 13th European Hematology Association Congress
Health Economic Analysis Reports That Revlimid is a Cost Effective Treatment for Multiple Myeloma
Preliminary Results from International Study Report That REVLIMID(R) Provides Responses for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
New Analysis of Phase III Studies Shows That REVLIMID(R) Plus Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life Years for Patients with Multiple Myeloma
Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
VIDAZA(R) Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU
Celgene Corporation to Present at Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Celgene Corporation to Present at Goldman Sachs 29th Annual Global Healthcare Conference
Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
Data from Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
Celgene Corporation to Present at FBR Capital Markets Spring Investor Conference
Seven Summits Research Releases Alerts on GS, APA, CELG, WAG, and KBH - May 27 2008 1:00AM
Celgene Corporation to Present at 2008 Citi Investment Research Global Healthcare Conference - May 27 2008 12:57AM
Celgene Corporation to Present at NASDAQ OMX 21st Investor Program - May 27 2008 12:57AM
Celgene Corporation to Present at The Seventh Annual JMP Securities Research Conference - May 27 2008 12:57AM
New Analyst Reports for CELGENE CORP, TOWER SEMICONDUCTOR LTD, YRC WORLDWIDE INC, and SBA COMMUNICATIONS - May 27 2008 1:27AM